MedCity News July 29, 2024
Jess Ross

As the FDA stakes its claim as the primary regulator of AI in healthcare, it must navigate the delicate balance between fostering innovation and ensuring safety and responsibility.

Innovation is not just a luxury but a necessity in the realm of clinical trials, particularly as we strive to accelerate drug development. Yet, the slow pace of innovation within the U.S. clinical trials system has impeded progress, leaving many stakeholders frustrated. U.S. Food and Drug Administration (FDA) resource limitations cause the inadvertent prioritization of programs sponsored by pharmaceutical companies, resulting in a bottleneck that stifles the adoption of more efficient and patient-friendly methods. Thus, expected breakthroughs from pharma have not materialized, leaving patients and researchers at a standstill.

Pharmaceutical companies...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Clinical Trials, Congress / White House, Govt Agencies, Regulations, Technology, Trends
Future Trends for Clinical Trials in 2025 and Beyond
The Future of Clinical Trials: Four Key Trends to Watch in 2025
Small cell lung cancer: Navigating the global clinical trial landscape
Generative AI has ‘potential to revolutionise clinical development’
Treating Covid burnout with ’shrooms

Share This Article